Inhibitors of the Cyclic GMP-AMP Synthase (cGAS) as Potential Treatment for Autoimmune and Inflammatory Diseases.

The invention in this patent application relates to macrocyclic benzimidazole derivatives represented herein generally by Formula 1. The compounds of Formula 1 are cGAS inhibitors and may potentially provide treatments of autoimmune diseases such as systemic lupus erythematosus, systemic sclerosis (SSc), interferonopathies, and others.